Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 2;4(9):e54. doi: 10.1038/emi.2015.54

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Shanghai Shangyixun Cultural Communication Co., Ltd

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Serologic reactivity of recombinant EF-Tu (rEF-Tu) in infected mice and Lyme disease patients. (A) SDS-PAGE showing purified recombinant EF-Tu protein. Predicted size and observed size for B. burgdorferi EF-Tu is 43 kDa and 47 kDa, respectively. (B) Immunoblotting of rEF-Tu using sera collected from C3H/HeN mice infected with B. burgdorferi strain 5A4NP1. Mouse sera used were collected at 2, 3, 4, 6 weeks of post-infection (1:600 dilution). *, HS stands for hyperimmune sera from mice immunized with rEF-Tu (αEF-Tu, 1:10000 dilution). ^, N stands for sera from naïve mice (1:600 dilution). (C) Representative immunoblotting results showing serologic reactivity of rEF-Tu in Lyme disease patients. Strips C-K are rEF-Tu probed with sera from ten different Lyme disease patients randomly selected from the CDC Lyme disease patient sera panel (1:100 dilution).